New Products at AACC Improve Efficiency and Accuracy in Clinical
Laboratories
LOS ANGELES--(BUSINESS WIRE)--Jul. 17, 2012--
Thermo Fisher Scientific Inc. (NYSE:TMO), the world leader in serving
science, today highlighted its comprehensive range of specialty
diagnostics products at the annual conference of the American
Association for Clinical Chemistry (AACC). The company continued its
focus on helping customers to improve productivity by introducing
products that drive innovation in the clinical laboratory, from sample
collection and storage to new immunoassays and quality controls. A
number of new products are being showcased at Thermo
Scientific booth 2215 during the Clinical Lab Expo at the AACC
conference, being held at the Los Angeles Convention Center from July
17-19.
“Healthcare professionals increasingly rely on new diagnostic tools to
provide the information they need to make critical decisions involving
patient care,” said Marc N. Casper, president and chief executive
officer of Thermo Fisher Scientific. “Our growing offering of specialty
diagnostics enables physicians to make faster, more accurate diagnoses
with the goal of improving patient outcomes.”
Solutions to Improve Productivity in the Clinical Laboratory
Thermo Fisher announced that its new Thermo
Scientific QMS™ Tacrolimus immunoassay has been CE marked
for sale in the European Union. The liquid, ready-to-use immunoassay
provides bar-coded reagents to run on the Thermo Scientific Indiko
bench-top chemistry analyzer. The product is not yet available for sale
in the United States.
The company also introduced a new generation of its Indiko platform, the Thermo
Scientific Indiko® Plus® analyzer.
Featuring the same compact design as its predecessor, the Indiko Plus
analyzer is designed to deliver higher throughput for routine clinical
research applications, including drugs-of-abuse testing and therapeutic
drug monitoring.
In addition, Thermo Fisher introduced immunoassay and chemistry controls
that improve the clinical laboratory workflow by concentrating the
number of analytes in a single vial. The new Thermo
Scientific MAS Omni·CORE™ control consolidates general chemistry
and serum protein quality control (QC) processing into a single solution
that offers different levels of testing to streamline the workflow and
reduce cost. The company’s new Thermo
Scientific MAS Omni·Immune™ immunoassay control consolidates
routine immunoassay, tumor marker and specialty immunoassay QC
processing.
Leading Portfolio of Immunodiagnostics for Improved Patient Care
Thermo Fisher continues to expand its extensive capabilities in the
clinical diagnosis and monitoring of allergies, asthma and autoimmune
diseases by introducing several new assays at AACC. The Thermo
Scientific EliA™ Rheumatoid Factor Assays,
cleared by the FDA in Nov. 2011, provides clinicians with a reliable and
simple tool to aid in the early diagnosis of rheumatoid arthritis. In
addition, Thermo
Scientific ImmunoCAP™ Tryptase Assay, cleared by the FDA in Feb.
2012, measures levels of a specific enzyme in serum or plasma to
provides an earlier indication of systemic mastocytosis, a rare blood
disorder.
For more information on Thermo Fisher’s specialty diagnostics products
being highlighted at AACC, please visit Thermo Scientific booth 2215 or
visit the online media room at www.thermofisher.com/news.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving
science. Our mission is to enable our customers to make the world
healthier, cleaner and safer. With revenues of $12 billion, we have
approximately 39,000 employees and serve customers within pharmaceutical
and biotech companies, hospitals and clinical diagnostic labs,
universities, research institutions and government agencies, as well as
in environmental and process control industries. We create value for our
key stakeholders through three premier brands, Thermo Scientific, Fisher
Scientific and Unity™ Lab Services, which offer a unique combination of
innovative technologies, convenient purchasing options and a single
solution for laboratory operations management. Our products and services
help our customers solve complex analytical challenges, improve patient
diagnostics and increase laboratory productivity. Visit www.thermofisher.com.
The following constitutes a “Safe Harbor” statement under the Private
Securities Litigation Reform Act of 1995: This press release contains
forward-looking statements that involve a number of risks and
uncertainties. Important factors that could cause actual results to
differ materially from those indicated by such forward-looking
statements are set forth in the company’s Quarterly Report on Form 10-Q
for the quarter ended March 31, 2012, under the caption “Risk Factors,”
which is on file with the Securities and Exchange Commission and
available in the “Investors” section of our website under the heading
“SEC Filings.” Important factors that could cause actual results to
differ materially from those indicated by forward-looking statements
include risks and uncertainties relating to: the need to develop new
products and adapt to significant technological change; implementation
of strategies for improving growth; general worldwide economic
conditions and related uncertainties; dependence on customers' capital
spending policies and government funding policies; the effect of
exchange rate fluctuations on international operations; the effect of
healthcare reform legislation; use and protection of intellectual
property; the effect of changes in governmental regulations; and the
effect of laws and regulations governing government contracts, as well
as the possibility that expected benefits related to the acquisitions of
Dionex and Phadia may not materialize as expected. While we may elect to
update forward-looking statements at some point in the future, we
specifically disclaim any obligation to do so, even if estimates change
and, therefore, you should not rely on these forward-looking statements
as representing our views as of any date subsequent to today.
Source: Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc.
Media:
Ron O’Brien, 781-622-1242
ron.obrien@thermofisher.com
www.thermofisher.com
or
Investor:
Ken
Apicerno, 781-622-1294
ken.apicerno@thermofisher.com
